The FDA has approved the first all-oral, fixed-duration first-line regimen for treatment of chronic lymphocytic leukemia and ...
FDA cleared acalabrutinib plus venetoclax as the only all-oral, fixed-dose combination option for first-line, treatment-naïve CLL/SLL. Phase 3 AMPLIFY showed superior PFS versus chemoimmunotherapy, ...
Gilead Sciences, Inc. shares have risen more than 43% over the past year. Click here to find out why GILD stock is a Sell.
AstraZeneca has secured a key regulatory win in its effort to reclaim the lead in the BTK inhibitor market, with the FDA approving its combination of Calquence plus Venclexta as the first all-oral, ...
Discarded, doubted and defined by structure in Los Angeles, Jared Goff arrived in Detroit as a bridge quarterback. Four seasons later, the film and the numbers tell a different story: he’s not just ...
Spring practices are less than 48 hours away for Nebraska football. Ahead of an earlier-than-normal slate of 15 practices, ...
Treatment approaches have shifted with the introduction of targeted agents, notably Bruton tyrosine kinase (BTK) inhibitors, ...
New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO beyond lung ...
Researchers evaluated a different chemo regimen in combination with Braftovi and Erbitux, which is already approved with mFOLFOX6.
The FDA approved a once-monthly Rybrevant Faspro schedule with Lazcluze for first-line EGFR-mutated advanced NSCLC, reducing visits.
That track record is fueling a concentrated push among clinical-stage oncology companies toward registration-directed study designs in high-unmet-need tumor types, as demonstrated by Oncolytics ...
We've taken a look at the statistically-backed strongest Newcastle United line-up in this season's Champions League.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results